"That's my view. They'll cut preemptively in June. That is to say Wednesday," says the Grant's Interest Rate Observer newsletter editor.Economyread more
Sotheby's announced Monday that it's signed an agreement to be acquired by BidFair USA, a venture owned by art collector Patrick Drahi.Marketsread more
Iran will surpass the internationally agreed levels of its low-enriched uranium levels in 10 days, the country's atomic energy body said Monday.Politicsread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
Ross played down the prospect of an agreement being reached at the G-20 meeting in Osaka on June 28-29.Paris Airshowread more
Boeing is scrambling to restore confidence in the 737 Max from regulators, customers and the flying public.Paris Airshowread more
Google CEO Sundar Pichai said in a CNN interview that while the company will work to remove as much harmful content as possible, the company can't remove 100% of it.Technologyread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
In a rare downgrade for the stock, Imperial Capital lowered its rating for Disney to in-line from outperform and maintained its target price of $147.Investingread more
Atlassian is releasing a document that's meant to simplify the negotiation of terms for acquisitions. That way the buyer and seller can focus on more important topics, like...Technologyread more
A closely followed gauge of manufacturing in the New York area fell this month to its lowest level in nearly three years.Economyread more
A drug originally designed as a treatment for the bone-thinning disease, osteoporosis, is being considered as a possible breakthrough treatment for bald people.
Currently only two drugs — minoxidil and finasteride — are available for treatment of male-pattern balding (androgenetic alopecia). A project by The University of Manchester's Centre for Dermatology Research in England began work by examining an immunosuppressive drug that had long been known to cause hair growth as a side effect.
This drug, Cyclosporine A (CsA), has been commonly used since the 1980s to suppress transplant rejection and autoimmune diseases. The project team discovered that CsA restricts a protein that when otherwise left alone, slows the growth of hair follicles. Hair growth, however, is the least problematic side-effect of CsA, leading project leader, Nathan Hawkshaw, to look for another solution.
After some research, he discovered that a separate compound developed to tackle osteoporosis also suppressed the bald-causing protein in the same manner. Better yet, scientists believe this drug, titled "WAY-316606," can be administered without dramatic side-effects.
The study was published Tuesday in the open access journal PLOS Biology. On release of the report, Hawkshaw said successful experiments were carried out using scalp hair follicles that had been donated by over 40 patients.
"This makes our research clinically very relevant, as many hair research studies only use cell culture," he said.
Hawkshaw said the next step should be a clinical trial to determine whether WAY-316606, or similar compounds, are effective and safe.